Iqirvo

Elafibranor, the active ingredient in Iqirvo, is a PPARα/δ agonist presented as an oral tablet for oral use. It treats primary biliary cholangitis in adults who have an inadequate response to ursodeoxycholic acid. The medication is indicated for patients with persistent cholestasis despite standard therapy and aims to improve liver biochemistry and delay disease progression.

GNH USA supplies Iqirvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers, ensuring product integrity throughout the supply chain.

Iqirvo acts on the cholestatic liver disease pathway, specifically primary biliary cholangitis.

Primary biliary cholangitis: improves liver enzyme levels and may slow disease progression in adults with inadequate response to ursodeoxycholic acid.

Elafibranor may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Diarrhea: loose stools. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Elevated liver enzymes: significant increase in ALT/AST. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: abdominal pain with elevated enzymes.

When prescribing Iqirvo, clinicians should consider several precautionary measures. - Liver monitoring: regularly assess ALT, AST, and bilirubin levels. - Drug interactions: review concomitant medications for potential PPAR agonist interactions. - Pregnancy and lactation: avoid use unless benefits outweigh risks; limited data available. - Gastrointestinal symptoms: counsel patients to report persistent nausea or diarrhea. - Discontinue if serious adverse events occur: stop therapy and seek medical evaluation. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Elafibranor can interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase Elafibranor plasma concentrations. - Concurrent use of other PPAR agonists: risk of additive effects on lipid metabolism.

Moderate Interactions (Monitor Closely): - Statins: monitor for increased risk of myopathy. - Anticoagulants (e.g., warfarin): observe INR for potential alterations.